Development of alopecia areata universalis in a patient receiving adalimumab [6]

Archives of Dermatology

Volumn 142, Issue 12, 2006, Pages 1654-1655

  Garcia Bartels, Natalie ^a   Lee, Hae Huyk ^b   Worm, Margitta ^b   Burmester, Gerd Rüdiger ^b   Sterry, Wolfram ^b   Blume Peytavi, Ulrike ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DEXAMETHASONE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; ROFECOXIB;

ADULT; ALOPECIA AREATA; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS;

ADULT; ALOPECIA AREATA; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845684650     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.12.1654     Document Type: Letter

References (4)

1. McElwee KJ, Hoffmann R, Freyschmidt-Paul P, et al. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells. J Invest Dermatol. 2002;119:1426-1433.
2. Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082-1084.
3. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles [letter]. Arch Dermatol. 2004;140:1012.
4. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol. 2005;141:759-760.